Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Schrump Website

David S. Schrump, M.D.

Selected Publications

1)  Miller AC, Rosati SF, Suffredini AF, Schrump DS.
A systematic review and pooled analysis of CPR-associated cardiovascular and thoracic injuries.
Resuscitation. 85: 724-31, 2014.
2)  Schrump DS.
Invited commentary.
Ann. Thorac. Surg. 97: 1045, 2014.
3)  Miller AC, Miettinen M, Schrump DS, Hassan R.
Malignant Mesothelioma and Central Nervous System Metastases: Report of two cases, Pooled Analysis and Systematic Review.
Ann Am Thorac Soc. 2014.
4)  Zhang Y, Calado R, Rao M, Hong JA, Meeker AK, Dumitriu B, Atay S, McCormick PJ, Garfield SH, Wangsa D, Padilla-Nash HM, Burkett S, Zhang M, Kunst TF, Peterson NR, Xi S, Inchauste S, Altorki NK, Casson AG, Beer DG, Harris CC, Ried T, Young NS, Schrump DS.
Telomerase Variant A279T Induces Telomere Dysfunction and Inhibits Non-Canonical Telomerase Activity in Esophageal Carcinomas.
PLoS ONE. 9: e101010, 2014.
5)  Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD.
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 927: 142-6, 2013.
6)  Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, Arai A, Schrump DS, Kwong KF, Rajan A, Giaccone G.
Characterization and management of cardiac involvement of thymic epithelial tumors.
J Thorac Oncol. 8: 246-9, 2013.
7)  Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, Zhang M, Kunst TF, Mercedes L, Schrump DS.
Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis.
J. Clin. Invest. 123: 1241-61, 2013.
8)  Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, Back T, Song NY, Datla M, Sun Z, Goldszmid R, Lin F, Cohoon T, Pike K, Wu X, Schrump DS, Wong KK, Young HA, Trinchieri G, Wiltrout RH, Hu Y.
The Pivotal Role of IKKa in the Development of Spontaneous Lung Squamous Cell Carcinomas.
Cancer Cell. 23: 527-40, 2013.
9)  Portal-Nuñez S, Shankavaram UT, Rao M, Datrice N, Atay S, Aparicio M, Camphausen KA, Fernández-Salguero PM, Chang H, Lin P, Schrump DS, Garantziotis S, Cuttitta F, Zudaire E.
Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice.
Cancer Res. 72: 5790-800, 2012.
10)  Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF.
Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.
Blood. 119: 5688-96, 2012.
11)  Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P, Mani H, Zlott D, Robey R, Bates SE, Li X, Rao M, Schrump DS.
Mithramycin Represses Basal and Cigarette Smoke-Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells.
Cancer Res. 72: 4178-92, 2012.
12)  Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, Zhu YJ, Ripley RT, Mathur A, Liu F, Yang M, Meltzer PA, Marquez VE, De Rienzo A, Bueno R, Schrump DS.
Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Clin. Cancer Res. 18: 77-90, 2012.
13)  Schrump DS.
Targeting epigenetic mediators of gene expression in thoracic malignancies.
Biochim. Biophys. Acta. 1819: 836-45, 2012.
14)  Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
J. Immunol. 186: 685-96, 2011.
15)  Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH.
ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.
J. Pediatr. Hematol. Oncol. 33: 360-8, 2011.
16)  Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, Lerman MI, Childs RW.
Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.
Oncogene. 30: 4697-706, 2011.
17)  Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS.
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.
Cancer Res. 71: 4192-204, 2011.
18)  Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I.
Operative management for recurrent and metastatic adrenocortical carcinoma.
J. Surg. Oncol. 105: 709-13, 2011.
19)  Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C, Keresztes R, Beneck D, Paul S, Stiles BM, Zhang Y, Schrump DS.
Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
J Thorac Oncol. 6: 1121-7, 2011.
20)  Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T, Schrump DS.
Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience.
Ann. Thorac. Surg. 92: 1195-200, 2011.
21)  Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L.
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.
Nat. Immunol. 12: 1230-7, 2011.
22)  Xi S, Yang M, Tao Y, Xu H, Shan J, Inchauste S, Zhang M, Mercedes L, Hong JA, Rao M, Schrump DS.
Cigarette smoke induces C/EBP-β-mediated activation of miR-31 in normal human respiratory epithelia and lung cancer cells.
PLoS ONE. 5: e13764, 2010.
23)  Butler PW, Cochran CS, Merino MJ, Nguyen DM, Schrump DS, Gorden P.
Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy.
Pituitary. 15: 260-5, 2010.
24)  Liu F, Killian JK, Yang M, Walker RL, Hong JA, Zhang M, Davis S, Zhang Y, Hussain M, Xi S, Rao M, Meltzer PA, Schrump DS.
Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate.
Oncogene. 29: 3650-64, 2010.
25)  Hong JJ, Schrump DS, Hughes MS.
Image of the month. Cystic parathyroid adenoma.
Arch Surg. 145: 705, 2010.
26)  Matsuda KM, Nóbrega R, Quezado M, Schrump DS, Filie AC.
Melanocytic bronchopulmonary carcinoid tumor in a patient with multiple endocrine neoplasia syndrome type 1: a case report with emphasis on intraoperative cytological findings.
Diagn. Cytopathol. 38: 669-74, 2010.
27)  Kemp CD, Kitano M, Kerkar S, Ripley RT, Marquardt JU, Schrump DS, Avital I.
Pulmonary resection for metastatic gastric cancer.
J Thorac Oncol. 5: 1796-805, 2010.
28)  Klapper JA, Davis JL, Ripley RT, Smith FO, Nguyen DM, Kwong KF, Mercedes L, Kemp CD, Mathur A, White DE, Dudley ME, Wunderlich JR, Rosenberg SA, Schrump DS.
Thoracic metastasectomy for adoptive immunotherapy of melanoma: A single-institution experience.
J. Thorac. Cardiovasc. Surg. 140: 1276-82, 2010.
29)  Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN.
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
J. Natl. Cancer Inst. 102: 271-4, 2010.
30)  Calado RT, Regal JA, Kleiner DE, Schrump DS, Peterson NR, Pons V, Chanock SJ, Lansdorp PM, Young NS.
A spectrum of severe familial liver disorders associate with telomerase mutations.
PLoS ONE. 4: e7926, 2009.
31)  Schrump DS.
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
Clin. Cancer Res. 15: 3947-57, 2009.
32)  Stockwin LH, Vistica DT, Kenney S, Schrump DS, Butcher DO, Raffeld M, Shoemaker RH.
Gene expression profiling of alveolar soft-part sarcoma (ASPS).
BMC Cancer. 9: 22, 2009.
33)  Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, Quezado M, Goldspiel BR, Venkatesan A, Berger A, Walker M, Toomey MA, Steinberg SM, Giaccone G, Rosenberg SA, Avital I.
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Trials. 10: 121, 2009.
34)  Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH.
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
J. Pediatr. Hematol. Oncol. 31: 561-70, 2009.
35)  Hussain M, Rao M, Humphries AE, Hong JA, Liu F, Yang M, Caragacianu D, Schrump DS.
Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells.
Cancer Res. 69: 3570-8, 2009.
36)  Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, Schrump DS.
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Cancer Biol. Ther. 7, 2008.
37)  Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, Fang BL, Nguyen DM.
Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.
Cancer Gene Ther. 15: 356-70, 2008.
38)  Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM.
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clin. Cancer Res. 14: 188-98, 2008.
39)  Wargo JA, Robbins PF, Li Y, Zhao Y, El-Gamil M, Caragacianu D, Zheng Z, Hong JA, Downey S, Schrump DS, Rosenberg SA, Morgan RA.
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Cancer Immunol. Immunother. 58: 383-94, 2008.
40)  Yu X, Wang S, Chen GA, Hou C, Zhao M, Hong JA, Nguyen DM, Schrump DS.
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Cancer J. 13: 105-13, 2007.
41)  Kang Y, Hong JA, Chen GA, Nguyen DM.
Dynamic transcriptional regulatory complexes including BORIS, CTCF, and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
Oncogene. 26: 4394-403, 2007.
42)  Reddy RM, Ziauddin M, Yeow W, Baras A, Choa A, Shamimi-Noori S, Zou J, Schrump D, Nguyen D.
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin.
Apoptosis. 12: 55-71, 2007.
43)  Stewart JH, Tran TL, Levi N, Tsai WS, Schrump DS, Nguyen DM.
The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
J. Surg. Res. 141: 120-31, 2007.
44)  Seam N, Finkelstein SE, Gonzales DA, Schrump DS, Gladwin MT.
The workup of stridor: virtual bronchoscopy as a complementary technique in the diagnosis of subglottic stenosis.
Respir. Care. 52: 337-9, 2007.
45)  Schrump DS, Hong JA, Nguyen DM.
Utilization of chromatin remodeling agents for lung cancer therapy.
Cancer J. 13: 56-64, 2007.
46)  Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R.
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Cancer Res. 66: 7317-25, 2006.
47)  Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS.
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Cancer Res. 66: 1105-13, 2006.
48)  Tsai W, Reddy RM, Schrump DS, Nguyen DM.
Enhancement of Apo2L/TRAIL mediated cytotoxicity in esophageal cancer cells by cisplatin: recruitment of the mitochondria – dependent death signaling pathway.
Mol. Cancer Ther. 5: 2977-90, 2006.
49)  Risinger J, Chandramouli G, Maxwell L, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump D, Berchuck A, Lobanenkov V, Barrett J.
Global expression analysis of cancer-testis genes in uterine cancers reveals a high incidence of BORIS expression.
Clin Cancer Res. 13: 1713-9, 2006.
50)  Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM.
Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura.
Clin Cancer Res. 12: 5777-5785, 2006.
51)  Yeow WS, Ziauddin MF, Maxhimer JB, Shamimi-Noori S, Baras A, Chua A, Schrump DS, Nguyen DM.
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Br. J. Cancer. 94: 1436-45, 2006.
52)  Nguyen DM, Schrump DS.
Staging lung cancer in the genomic era.
Thorac. Surg. Clin. 16: 329-37, 2006.
53)  Cole GW, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS, Nguyen DM.
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
Anticancer Res. 26: 809-21, 2006.
54)  Nguyen DM, Yeow W, Ziauddin MF, Baras A, Tsai W, Reddy RM, Chua A, Cole GW, Schrump DS.
The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
Cancer J. 12: 257-73, 2006.
55)  Schrump DS, Nguyen DM.
Utilization of chromatin remodeling agents for lung cancer therapy.
Thorac. Surg. Clin. 16: 367-77, 2006.
56)  Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM, Tsai W, Cole GW, Schrump DS, Nguyen DM.
Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation.
Neoplasia. 8: 446-57, 2006.
57)  Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Cancer Res. 65: 7751-62, 2005.
58)  Kassis ES, Zhao M, Hong JA, Chen GA, Nguyen DM, Schrump DS.
Depletion of DNA methyltransferase(DNMT) 1 and/or 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.
J. Thorac. Cardiovasc. Surg. 131: 298-306, 2005.
59)  Maxhimer JB, Reddy RM, Zuo J, Cole GW, Schrump DS, Nguyen DM.
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
J. Thorac. Cardiovasc. Surg. 129: 53-63, 2005.
60)  Schrump DS, Nguyen DM.
Novel molecular targeted therapy for esophageal cancer.
J. Surg. Oncol. 92: 257-61, 2005.
61)  Srinivasan R, Filie A, Reynolds J, Chang R, Chow C, Schrump DS, Takahashi Y, Suffredini AF, Childs RW.
Positron emission tomography for lymphoma staging: tissue remains the issue.
J Natl Cancer Inst. 97: 611-3, 2005.
62)  Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Cancer Res. 65: 7763-74, 2005.
63)  Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS.
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.
Oncogene. 24: 2386-97, 2005.
64)  Schrump DS, Nguyen DM.
Targeting the epigenome for the treatment and prevention of lung cancer.
Semin. Oncol. 32: 488-502, 2005.
65)  Cole GW, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM.
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
J. Thorac. Cardiovasc. Surg. 129: 1010-7, 2005.
66)  Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS.
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.
Clin. Cancer Res. 10: 1813-25, 2004.
67)  Reddy RM, Tsai WS, Ziauddin MF, Zuo J, Cole GW, Maxhimer JB, Fang B, Schrump DS, Nguyen DM.
Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand.
J Thorac Cardiovasc Surg. 128: 883-91, 2004.
68)  Schrump DS.
Genomic surgery for lung cancer.
J Surg Res. 117: 107-13, 2004.
69)  Nguyen DM, Schrump DS.
Growth factor receptors as targets for lung cancer therapy.
Semin Thorac Cardiovasc Surg. 16: 3-12, 2004.
70)  Nguyen DM, Chen GA, Reddy R, Tsai W, Schrump WD, Cole G, Schrump DS.
Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
J Thorac Cardiovasc Surg. 127: 365-75, 2004.
71)  Feldman ED, Hughes MS, Stratton P, Schrump DS, Alexander HR.
Pseudo-Meigs' syndrome secondary to isolated colorectal metastasis to ovary: a case report and review of the literature.
Gynecol Oncol. 93: 248-51, 2004.
72)  Finkelstein SE, Summers RM, Nguyen DM, Schrump DS.
Virtual bronchoscopy for evaluation of airway disease.
Thorac Surg Clin. 14: 79-86, 2004.
73)  Suhler EB, Chan CC, Caruso RC, Schrump DS, Thirkill C, Smith JA, Nussenblatt RB, Buggage RR.
Clinicopathologic reports, case reports, and small case series: presumed teratoma-associated paraneoplastic retinopathy.
Arch Ophthalmol. 121: 133-7, 2003.
74)  Finkelstein SE, Schrump DS, Nguyen DM, Hewitt SM, Kunst TF, Summers RM.
Comparative Evaluation of Super High-Resolution CT Scan and Virtual Bronchoscopy for the Detection of Tracheobronchial Malignancies.
Chest. 124: 1834-1840, 2003.
75)  Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JH, Steiner F, Schrump DS.
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
J Thorac Cardiovasc Surg. 125: 1132-42, 2003.
76)  Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M.
Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.
Lab Invest. 83: 1255-65, 2003.
77)  Finkelstein SE, Schrump DS, Nguyen DM, Mullick R, Summers RM.
Novel thoracic imaging augments diagnosis of bronchial obstruction.
Ann Thorac Surg. 76: 296, 2003.
78)  Finkelstein SE, Schrump DS, Nguyen DM, Mullick R, Summers RM.
Novel thoracic imaging augments diagnosis of bronchial obstruction.
Ann Thorac Surg. 76: 296, 2003.
79)  Gibril F, Chen YJ, Schrump DS, Vortmeyer A, Zhuang Z, Lubensky IA, Reynolds JC, Louie A, Entsuah LK, Huang K, Asgharian B, Jensen RT.
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1.
J Clin Endocrinol Metab. 88: 1066-81, 2003.
80)  Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, Merino MJ, Schrump DS, Libutti SK, Alexander HR, Sarlis NJ.
Role of metastasectomy in the management of thyroid carcinoma: The NIH experience.
J Surg Oncol. 82: 10-8, 2003.
81)  Stewart JH, Nguyen DM, Chen GA, Schrump DS.
Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.
J Thorac Cardiovasc Surg. 123: 295-302, 2002.
82)  Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS.
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.
J Natl Cancer Inst. 94: 504-13, 2002.
83)  Schrump DS, Zhai S, Nguyen DM, Weiser TS, Fisher BA, Terrill RE, Flynn BM, Duray PH, Figg WD.
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques.
J Thorac Cardiovasc Surg. 123: 686-94, 2002.
84)  Schrump DS, Nguyen DM, Kunst TE, Hancox A, Figg WD, Steinberg SM, Pishchik V, Becerra Y.
Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura.
Clin Lung Cancer. 4: 186-92, 2002.
85)  Finkelstein SE, Summers RM, Nguyen DM, Stewart JH, Tretler JA, Schrump DS.
Virtual bronchoscopy for evaluation of malignant tumors of the thorax.
J Thorac Cardiovasc Surg. 123: 967-72, 2002.
86)  Abou-Saif A, Lei J, McDonald TJ, Chakrabarti S, Waxman IF, Shojamanesh H, Schrump DS, Kleiner DE, Gibril F, Jensen RT.
A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer.
Gastroenterology. 120: 1271-8, 2001.
87)  Nguyen DM, Lorang D, Chen GA, Stewart JH, Tabibi E, Schrump DS.
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
Ann Thorac Surg. 72: 371-8; discussion 378-9, 2001.
88)  Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM, Schrump DS.
Induction of MAGE-3 expression in lung and esophageal cancer cells.
Ann Thorac Surg. 71: 295-301; discussion 301-2, 2001.
89)  Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS.
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
J Immunother. 24: 151-61, 2001.
90)  Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, Stewart JH, Nguyen DM, Rosenberg SA, Schrump DS.
Sequential 5-Aza-2'-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1.
J Immunother. 24: 151-161, 2001.
91)  Schrump DS, Waheed I.
Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas.
Semin Cancer Biol. 11: 73-80, 2001.
92)  Schrump DS, Nguyen DM.
Targets for molecular intervention in multistep pulmonary carcinogenesis.
World J Surg. 25: 174-83, 2001.
93)  Schrump DS, Nguyen DM.
The epidermal growth factor receptor-STAT pathway in esophageal cancer.
Cancer J. 7: 108-11, 2001.
94)  Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Schrump DS, Shin DM, Walsh GL, Roth JA.
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
Cancer Gene Ther. 7: 530-6, 2000.
95)  Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS.
Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin.
Ann Thorac Surg. 70: 1853-60, 2000.
96)  Feingold DL, Alexander HR, Chen CC, Libutti SK, Shawker TH, Simonds WF, Marx SJ, Skarulis MC, Doppman JL, Schrump DS, Bartlett DL.
Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas.
Surgery. 128: 1103-9;discussion 1109-10, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/11/2014.